Machina Capital S.A.S. Boosts Stake in Hologic, Inc. $HOLX

Machina Capital S.A.S. raised its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 264.9% during the 3rd quarter, Holdings Channel reports. The fund owned 18,494 shares of the medical equipment provider’s stock after purchasing an additional 13,426 shares during the period. Machina Capital S.A.S.’s holdings in Hologic were worth $1,248,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Invesco Ltd. increased its position in Hologic by 72.5% during the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock valued at $543,486,000 after buying an additional 3,505,828 shares in the last quarter. K.J. Harrison & Partners Inc purchased a new stake in shares of Hologic during the second quarter worth about $1,987,000. Aberdeen Group plc increased its holdings in shares of Hologic by 2.8% during the second quarter. Aberdeen Group plc now owns 244,997 shares of the medical equipment provider’s stock valued at $15,964,000 after acquiring an additional 6,589 shares in the last quarter. Nordea Investment Management AB increased its holdings in shares of Hologic by 7.2% during the second quarter. Nordea Investment Management AB now owns 2,587,414 shares of the medical equipment provider’s stock valued at $168,674,000 after acquiring an additional 174,828 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Hologic in the 3rd quarter valued at approximately $4,170,000. 94.73% of the stock is owned by institutional investors.

Hologic Stock Down 0.1%

Shares of HOLX opened at $74.59 on Thursday. The stock’s 50-day moving average price is $74.88 and its 200-day moving average price is $71.13. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $16.65 billion, a price-to-earnings ratio of 31.08, a PEG ratio of 2.23 and a beta of 0.72. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $75.36.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. The company’s revenue was up 2.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.87 earnings per share. On average, sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. BNP Paribas Exane downgraded Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target on the stock. in a research note on Friday, November 21st. Stephens cut Hologic from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $78.00 to $76.00 in a research note on Wednesday, October 22nd. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Hologic in a report on Tuesday, October 21st. Three analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $78.42.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.